Genetic Immunity
8300 Greensboro Drive
Suite 800
McLean
Virginia
22102
United States
Tel: 703-883-0312
Website: http://www.geneticimmunity.com/
24 articles about Genetic Immunity
-
Genetic Immunity Expands JSC Pharmadis Partnership by Granting 20 Cancer Vaccine Licenses for Russia and Commonwealth of Independent States
1/29/2019
Genetic Immunity, a clinical stage biotechnology company, is pleased to announce that it is expanding its collaboration with JSC Pharmadis by granting licenses to twenty cancer indications of its trans-dermally delivered pDNA-based vaccine technology.
-
Genetic Immunity Grants Exclusive License of Therapeutic HIV Vaccine Technology to JSC Pharmadis for Russia and Commonwealth of Independent States
12/18/2018
Pharmadis received rights to market Genetic Immunity's HIV technology in Russia and the Commonwealth of Independent States
-
Genetic Immunity Presents at First Russian-Chinese HIV Congress in Moscow
12/5/2018
Genetic Immunity is pleased to announce that it was invited to present at the first Russian-Chinese HIV Congress in Moscow.
-
Genetic Immunity Receives GMP Certification for in-House Manufacturing Facility
10/8/2012
-
Genetic Immunity Clinical Trial Data Published in PLoS ONE
5/17/2012
-
Genetic Immunity Presents the DermaPrep Transdermal Delivery System and DermaVir Nanomedicine-based Therapeutic Vaccine for HIV/AIDS at HIV DART 2010 Drug Development Conference
12/9/2010
-
Immunacia's Genetic Immunity Reports Phase II Data on DermaVir, a Therapeutic Vaccine for HIV/AIDS, During the XVIII International AIDS Conference: A 70% Viral Load Reduction Demonstrated in HIV Drug-naive Individuals
7/19/2010
-
Immunacia's Genetic Immunity Presents DermaVir at the 7th International Conference on Nanosciences & Nanotechnologies – A Unique Nanomedicine for Therapeutic HIV Vaccine
7/12/2010
-
Genetic Immunity Develops Unique Nanomedicine Formulation for DermaVir Therapeutic Vaccine for HIV/AIDS
5/13/2010
-
Dr. James Chafouleas Joins ViroStatics and Genetic Immunity as Strategic Adviser
5/3/2010
-
Genetic Immunity Presents DermaVir at DNA Vaccines 2010 Conference – Unique Nanomedicine Formulation and Topical Administration of an HIV/AIDS Therapeutic Vaccine
3/2/2010
-
Genetic Immunity, InPlay: Company Completes Patient Enrollment in Italian Phase II Trial of DermaVir Patch HIV Immunotherapeutic Nanomedicine
7/1/2009
-
Genetic Immunity: Company to Present at Phacilitate Ltd's 8th Annual European Vaccine Forum
6/18/2009
-
Genetic Immunity, InPlay: Company Completes Patient Enrollment in Phase II Trial of DermaVir Patch HIV Immunotherapeutic Nanomedicine Lead Product Candidate
6/11/2009
-
Genetic Immunity, InPlay: Second Phase II Clinical Trial Commences in Italy on Company's Lead Product Candidate DermaVir Patch HIV Vaccine
4/16/2009
-
Genetic Immunity, InPlay: Genetic Immunity Licenses Plasmid DNA Purification Technology
4/1/2009
-
Genetic Immunity, InPlay: Genetic Immunity Receives CE Marking for DermaPrep, a Unique Transdermal Delivery Device
3/11/2009
-
Genetic Immunity, Retrospective: Phase 1 Trial Results for the Company's HIV Vaccine Candidate Lead Product
3/4/2009
-
Genetic Immunity, Retrospective: Next Generation DNA Vaccine - DermaVir Nanomedicine for the Treatment of HIV/AIDS
2/26/2009
-
Genetic Immunity Announces First Patient Dosed In Phase II Trial With DermaVir Patch For HIV Disease
11/14/2008